Moclobemide in patients with
dementia and depression

Amrein R, Martin JR, Cameron AM
F. Hoffmann-La Roche, Ltd.,
Basel, Switzerland.
Adv Neurol 1999; 80:509-19

ABSTRACT

Moclobemide, the first reversible inhibitor of MAOA (so-called RIMA) to become widely available for clinical use, is an effective and well-tolerated antidepressant. Preclinical experiments, as well as studies in human volunteers and patients, provide evidence for the cognition enhancing effects of moclobemide. This cognition improvement, taken together with moclobemide's absence of anticholinergic effects, lack of sedation, and similarity in pharmacokinetics in young and elderly individuals, makes this drug especially appropriate for use in treatment of the elderly depressed patient.

Moclobemide research
                                                         
 1.    Moclobemide  for the treatment of depression
 2.    Moclobemide  in clinical psychopharmacology
 3.    Moclobemide  therapy for chronic depressive disorders 
 4.    Moclobemide  and tranylcypromine in depression
 5.    Moclobemide  and fluoxetine for panic disorder
 6.    Moclobemide  in patients with dementia and depression
 7.    Moclobemide  in mild major depression
 8.    Moclobemide  for depression
 9.    Moclobemide  in treatment of major depressive episodes
10.   Moclobemide  vs. placebo in the treatment of depression
11.   Moclobemide  long-term treatment in major depression
12.   Moclobemide  and sertraline in the treatment of depression
13.   Moclobemide  in long-term treatment
14.   Moclobemide  vs fluoxetine for double depression
15.   Moclobemide  vs fluoxetine in major depressive disorders
16.   Moclobemide  vs fluoxetine in major depression
         Moclobemide  manufacturer's product insert

 

 

Hit Counter